Firm’s NEAT technology allows gene-controlled joining of oligo probes in situ.

DxTerity Diagnostics and City of Hope are partnering to develop therapeutic applications for DxTerity’s NEAT™ technology. This genomics testing platform enables gene-controlled ligation of oligonucleotide probes inside cells.

The parties will use this technique to develop in situ assembled antisense therapeutics. The DxTerity approach reportedly differs from traditional antisense therapeutics, because the initial materials are designed to be inactive requiring in situ activation that is dependent on the expression of the target gene.

DxTerity explains that NEAT uses a chemical reaction for target and signal amplification, replacing enzymatic alternatives, to enable the development of simple and affordable nucleic acid-based tests.

“Our goal is to utilize the unique properties available with the NEAT technology to overcome some of the current limitations associated with antisense therapeutics,” remarks Arthur. D. Riggs, Ph.D., chair, department of diabetes and metabolic diseases research and Emeritus director, Beckman Research Institute of the City of Hope.

Previous articleAzur Pharma Acquires U.S. Rights to BioSante’s Estrogen Gel for $3.3M
Next articleForest Advises against $61M Unsolicited Mini-Tender Offer from TRC